Syschem India Ltd

Sustained unprofitability: net profit negative in 6 of the past 8 quarters (since Jun 2019); only Jun–Sep 2019 were profitable. Current ROE 0.62% despite zero financial leverage.

Revenue volatility with unexplained swings (₹11.86 Cr in Jun 2020 to ₹28.19 Cr in Sep 2019)—verify the causes and whether these reflect customer concentration or market instability.

Complete absence of institutional confidence: FII 0%, DII 0.16%; stock down 29.86% in one year from a 52-week high of ₹59.89.

Severely depressed operating margins (ranging from -16.63% to +2.19%) with recent deterioration to -16.63% (Mar 2021)—verify cost structure issues.

Revenue rebounded from Jun 2020's trough of ₹11.86 Cr to ₹23.33 Cr (Mar 2021); verify the drivers—new products, customer wins, or market factors.

Operating margins reached +2.19% (Jun 2019) and +1.24% (Sep 2019); verify which operational improvements enabled profitability then and whether they can be restored.

Zero debt (D/E = 0) provides financial flexibility for restructuring or strategic investments; verify management's plans to deploy this headroom.

Verify product pipeline strength, regulatory approvals in progress, and competitive positioning in target therapeutic segments.